Advertisement

Topics

Cyclosporine and Etanercept in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis

2016-12-08 17:38:23 | BioPortfolio

Summary

Defining the true effect of adjunctive therapy for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis (SJS/TEN) on time to full healing, mortality, and long-term outcomes represents a critical need in the field of dermatology and burn surgery. Collaborating with 20 sites from across North America we will determine if cyclosporine or etanercept therapy improves SJS/TEN short outcomes above supportive care alone The scientific premise for this study is that case series, cohorts, and small non-randomized studies have not supported the use of non-pulsed corticosteroids and intravenous immunoglobulin (IVIG), while showing the promise of cyclosporine and etanercept in reducing the time to complete re-epithelialization. By indirect comparison, etanercept appears to be superior in small studies, however none of the studies have evaluated these therapies in a blinded and randomized trial. Additionally, we will uncover the underlying process of SJS/TEN through the analysis of skin samples, blood, blister fluid and immune cells to study the immune system and changes in gene expression with and without drug therapy. This will improve the treatment of patients in the future.

Description

Aim 1: Establish the most effective therapy for SJS/TEN. A multi-centered, double-blind randomized control trial including 20 sites with an enrollment of 267 patients over 4 years will be undertaken to understand which of supportive care, cyclosporine or etanercept causes the greatest reduction in time to complete re-epithelialization. Assessment of the primary outcome will occur using a previously validated method consisting of two independent assessors and digital photograph analysis. Secondary outcomes will include all-cause mortality, time to cessation of disease progression, adverse effects related to a study medication, secondary chronic mucocutaneous morbidity, and hospital length of stay. Subgroup analysis will be performed to examine differences for treatment between gender, SCORTEN, percent body surface area (%BSA) and drug half-life.

Aim 2: Enhance our understanding of genetic and biomarker predictors in SJS/TEN. Genome sequencing and transcriptome profiling will be used to evaluate changes in expression over time within each treatment arm to identify involved genes and responses to treatment. Changes over the course of hospitalization and at the follow-up visit will be tested. Additionally, high resolution HLA and Mega chip typing will be performed on individuals with a clear drug cause according to the Algorithm of Drug Causality for Epidermal Necrolysis (ALDEN) Score. These will be matched to drug tolerant controls. Third, measurement of granulysin will occur at presentation and serial time points to establish its role as a predictive biomarker in disease prognosis and response to treatment.

Aim 3: To gain insights into the immunopathogenesis of SJS/TEN. We will collect blister fluid, skin biopsies and peripheral blood mononuclear cells (PBMCs) during the acute SJS/TEN reaction before treatment, following completion of treatment (PBMCs), and on follow-up from recovery PBMCs. This will analyze T-cell changes and gene expression as it relates to the disease and treatment. We expect that this will direct therapy for the future.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Conditions

Stevens-Johnson Syndrome

Intervention

cyclosporin A, Etanercept 50 MG Solution for Injection, Placebos

Status

Not yet recruiting

Source

Ottawa Hospital Research Institute

Results (where available)

View Results

Links

Published on BioPortfolio: 2016-12-08T17:38:23-0500

Clinical Trials [2450 Associated Clinical Trials listed on BioPortfolio]

Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids.

Patients diagnosed with Stevens-Johnson syndrome and Toxic Epidermal Necrolysis were confirmed based on the investigators national diagnostic criteria. Patients who meet all inclusion crit...

Stevens-Johnson Syndrome Antimicrobial

Steven-Johnson's syndrome, or great multiform erythema, appears as a systemic disturbance, with skin involvement and mucous membranes, related to several factors, such as, viral or bacteri...

Corneal Epitheliotropic Factors in Autologous Serum Eye Drops in Nonautoimmune and Stevens-Johnson Syndrome With Dry Eye

Autologous serum eye drops (ASE) have been becoming popular in treatment of severe dry eye for the past decade. One of the most beneficial properties of the ASE over artificial eye drops ...

Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis

This is a prospective, multicenter cohort observational; study to compare treatment outcomes in patients admitted to the hospital with Stevens-Johnsons Syndrome/Toxic Epidermolysis, aiming...

Topical Infliximab in Autoimmune Eyes With Keratoprosthesis

The Boston Keratoprosthesis type I (KPro) is a prosthetic cornea used to treat several causes of corneal blindness. Some categories of patients, including those with auto-immune diseases s...

PubMed Articles [10454 Associated PubMed Articles listed on BioPortfolio]

Stevens-Johnson Syndrome: A Challenging Diagnosis.

Stevens-Johnson syndrome is a rare, yet life-threatening, delayed-type hypersensitivity reaction characterized by mucocutaneous epidermal necrolysis. Toxic epidermal necrolysis is a severe manifestati...

Life-threatening dermatoses: Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Impact on the Spanish public health system (2010-2015).

Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) are serious mucocutaneous reactions. In Spain, the epidemiology and resulting expenses of these diseases are not well established.

Retrospective review of paediatric case reports of Stevens-Johnson syndrome and toxic epidermal necrolysis with lamotrigine from an international pharmacovigilance database.

This study aims to characterise paediatric reports with lamotrigine (LTG) and Stevens-Johnson syndrome or toxic epidermal necrolysis (SJS/TEN), and to explore whether potential risk factors can be ide...

Fluoxetine-induced Stevens-Johnson syndrome and liver injury.

Drug-induced liver injuries (DILI) are overall rare and often associated with use of medications. Medications are also the most common aetiology of Stevens-Johnson syndrome (SJS), but SJS is seldom se...

Corneal limbal stem cell deficiency in children with Stevens-Johnson syndrome.

To determine the incidence of corneal limbal stem cell deficiency (LSCD) as chronic ocular sequelae in children with Stevens-Johnson syndrome (SJS) / toxic epidermal necrolysis (TEN) and analyze the f...

Medical and Biotech [MESH] Definitions

A variant of bullous erythema multiforme. It ranges from mild skin and mucous membrane lesions to a severe, sometimes fatal systemic disorder. Ocular symptoms include ulcerative conjunctivitis, keratitis, iritis, uveitis, and sometimes blindness. The cause of the disease is unknown.

Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol.

Hypertonic sodium chloride solution. A solution having an osmotic pressure greater than that of physiologic salt solution (0.9 g NaCl in 100 ml purified water).

The injection of solutions into the skin by compressed air devices so that only the solution pierces the skin.

Interruption of the conduction of impulses in peripheral nerves or nerve trunks by the injection of a local anesthetic solution. (Stedman, 26th ed)

More From BioPortfolio on "Cyclosporine and Etanercept in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Complementary and Alternative Medicine
Alternative medicine are whole medical systems that did not fit with conventional medicine as they have completely different philosophies and ideas on the causes of disease, methods of diagnosis and approaches to treatment. Although often overlapping, co...

Dermatology
Acne Dermatology Eczema Psoriasis Wound Care Dermatology is the medical specialty concerned with the diagnosis and treatment of skin disorders (Oxford Medical Dictionary). As well as studying how the skin works, dermatology covers...


Searches Linking to this Trial